Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Usana Health Sciences (USNA) Other Operating Expenses (2016 - 2026)

Usana Health Sciences has reported Other Operating Expenses over the past 17 years, most recently at $88.7 million for Q2 2026.

  • Quarterly Other Operating Expenses fell 1.48% to $88.7 million in Q2 2026 from the year-ago period, while the trailing twelve-month figure was $348.3 million through Apr 2026, down 2.7% year-over-year, with the annual reading at $343.1 million for FY2026, 5.65% down from the prior year.
  • Other Operating Expenses was $88.7 million for Q2 2026 at Usana Health Sciences, down from $94.9 million in the prior quarter.
  • Over five years, Other Operating Expenses peaked at $161.2 million in Q1 2022 and troughed at $77.7 million in Q3 2025.
  • The 5-year median for Other Operating Expenses is $95.3 million (2024), against an average of $99.6 million.
  • Year-over-year, Other Operating Expenses plummeted 39.28% in 2022 and then rose 1.49% in 2026.
  • A 5-year view of Other Operating Expenses shows it stood at $97.9 million in 2022, then decreased by 2.04% to $95.9 million in 2023, then dropped by 2.48% to $93.5 million in 2024, then decreased by 16.92% to $77.7 million in 2025, then increased by 14.12% to $88.7 million in 2026.
  • Per Business Quant, the three most recent readings for USNA's Other Operating Expenses are $88.7 million (Q2 2026), $94.9 million (Q1 2026), and $77.7 million (Q3 2025).